Glenmark Pharmaceuticals Inc., USA, has announced the launch of Lacosamide Oral Solution, 10 mg/mL. The product is bioequivalent and therapeutically equivalent to Vimpat® Oral Solution, 10 mg/mL, by UCB, Inc.
According to IQVIA™ data, the Vimpat® Oral Solution market achieved annual sales of approximately $57.0 million for the 12-month period ending October 2024.
Marc Kikuchi, President & Business Head, North America, expressed his excitement, saying:
We are excited to announce the launch of Lacosamide Oral Solution, 10 mg/mL, strengthening our commitment to bring to market quality and affordable alternatives for patients.
Glenmark’s U.S. portfolio now includes 201 products authorized for distribution, with 51 ANDAs pending approval. The company remains committed to enhancing its product pipeline and expanding partnerships for growth.
Glenmark Pharmaceuticals is a globally recognized, research-driven pharmaceutical company with a strong presence across Branded, Generics, and OTC segments. The company focuses on key therapeutic areas, including respiratory, dermatology, and oncology. Glenmark operates 11 state-of-the-art manufacturing facilities spread across 4 continents and serves over 80 countries worldwide.
The company has consistently achieved global recognition, being ranked among the Top 100 Companies by R&D and Pharmaceutical Sales in 2022, as per In Vivo/Scrip 100. Additionally, Glenmark was placed in the Top 50 Generics and Biosimilars Companies by Sales in 2022, according to Generics Bulletin/In Vivo.
